ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma
Authors:
- P. SantoroPSP. Santoro
- P.F. FerrucciP.F. Ferrucci
- W. MingroneWMW. Mingrone
- E. CocorocchioECE. Cocorocchio
- A. ConconiACA. Conconi
- F.A. PeccatoriF.A. Peccatori
- K. De LuzioKLK. De Luzio
- C. MazzettaCMC. Mazzetta
- E. ZuccaEZE. Zucca
- F. CavalliFCF. Cavalli
- 1 January 2003
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (5) , 801-806
Abstract
The aim of this study is to verify the feasibility and the clinical activity of a new CHOP-like schedule (ACOD) with a fractionated days 1 and 8 administration in elderly patients. This regimen was chosen in the attempt to allow a sufficient dose intensity (DI) of each drug with better compliance. Fifty-two patients, (74 years, median age), with diffuse large B cell non-Hodgkin's lymphoma were retrospectively evaluated. Patients received ADM 25 mg/sqm, CTX 500 mg/sqm, VCR 1.2 mg/sqm (max 2 mg intravenously) days 1 and 8 and PDN 50 mg orally, days 1-8. Results showed that 54% of patients reached a complete remission, 21% a partial remission with an overall response rate of 75%. Two-thirds of the patients received at least 70% of the planned dose of cyclophosphamide and doxorubicin and 50% of vincristine and prednisone. The median duration of follow up was 12.6 months (range 0.7-61.4). The estimated median OS was 15.2 months (95%CI = [11.6, not estimable]); the estimated median PFS was 5.7 months (95%CI = [5.12, not estimable]). After 2 years, the proportion of patients alive was 47% (95%CI = 34-64%) and the proportion of patients free from progression was 39% (95%CI = 27-57%). Grade 3-4 leukopenia was observed in 61% of patients with 11% of febrile neutropenia. In conclusion, the ACOD chemotherapy regimen seems safe and feasible in elderly patients. This schedule allowed a sufficient DI of chemotherapic agents with clinical results very similar to those recorded with the standard CHOP regimen in young adults.Keywords
This publication has 19 references indexed in Scilit:
- Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.Journal of Clinical Oncology, 1998
- CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.Journal of Clinical Oncology, 1998
- Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.Journal of Clinical Oncology, 1995
- Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1995
- Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose Adriamycin-based regimensAnnals of Oncology, 1994
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocolAnnals of Oncology, 1993
- Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis.Journal of Clinical Oncology, 1990
- The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1988
- Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphomaThe American Journal of Medicine, 1987